Deep Track Capital PLRX Position
Exited7-Fund ConvergenceDeep Track Capital exited their position in Pliant Therapeutics Inc. (PLRX) in Q3 2025, after holding the stock for 11 quarters.
The position was first reported in Q1 2023 and has been tracked across 11 quarterly 13F filings.
PLRX is a convergence signal: 7 specialist biotech funds hold this stock, suggesting high institutional conviction.
About Pliant Therapeutics Inc.
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Full company profile →Short Interest
6.3%
6.0 days to cover
Deep Track Capital PLRX Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q3 2025 | Exited | 0 | -3,947,807 | $0 |
| Q2 2025 | Decreased | 3,947,807 | -1,451,874 | $4.6M |
| Q1 2025 | Decreased | 5,399,681 | -572,576 | $7.3M |
| Q4 2024 | Held | 5,972,257 | — | $78.7M |
| Q3 2024 | Held | 5,972,257 | — | $66.9M |
| Q2 2024 | Increased | 5,972,257 | +222,257 | $64.2M |
| Q1 2024 | Held | 5,750,000 | — | $85.7M |
| Q4 2023 | Increased | 5,750,000 | +250,000 | $104.1M |
| Q3 2023 | Increased | 5,500,000 | +1,450,000 | $95.4M |
| Q2 2023 | Increased | 4,050,000 | +627,943 | $73.4M |
| Q1 2023 | New | 3,422,057 | +3,422,057 | $91.0M |
Frequently Asked Questions
Does Deep Track Capital own PLRX?
No. Deep Track Capital exited their position in Pliant Therapeutics Inc. (PLRX) in Q3 2025. They previously held the stock for 11 quarters.
How many hedge funds own PLRX?
7 specialist biotech hedge funds currently hold PLRX, including Redmile Group, RA Capital Management, Casdin Capital and 4 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Deep Track Capital first buy PLRX?
Deep Track Capital's position in PLRX was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Deep Track Capital's PLRX position increasing or decreasing?
Deep Track Capital completely exited their PLRX position in the most recent quarter.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
PLRXCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Deep Track CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →